SpinalCyte earns international patent for biologic product: 3 insights

Biologics

SpinalCyte received a new Australian patent related to its fibroblast technology.

Here are three things to know:

1. CybroCell now comprises 36 U.S. and foreign issued patents with 40 pending.

2. The new patent involves differentiating human dermal fibroblast into chondrocyte-like cells by exposing them to a specific environment of growth factors, hypoxia, hydrostatic pressure and shear stress.

3. CybroCell is an off-the-shelf allogenic human dermal fibroblast product designed to treat degenerative disc disease.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers